A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

NCT04123470 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

GENETIC: delolimogene mupadenorepvec
BIOLOGICAL: atezolizumab

Sponsor

Lokon Pharma AB

Collaborators

[object Object]